INAB: Koefisien rega marang pendapatan IN8bio, Inc

Logo korporat perusahaan IN8bio Inc (INAB)

IN8bio, Inc. is implementing energy-efficient bioreactors and maintaining strict control over biomaterial disposal. The price-to-sales multiple helps identify market confidence in revenue, with the current value standing at . Experienced cell therapy leaders ensure transparency of R&D budgets and proficient interaction with regulators. The strategy is focused on completing mid-stage trials of gamma-delta T-cells and developing proprietary laboratory logistics to combat blood cancers.

INAB (IN8bio, Inc.) riwayat Rasio kapitalisasi pasar marang pendapatan saka 04.07.2022 nganti 13.11.2026

Rincian metrik komprehensif lan analitis IN8bio, Inc (INAB)

- rega saham lan target rega konsensus:
Kurs saham in8bio.com|INAB - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar IN8bio, Inc|INAB - Nilai Total Perusahaan
- rincian nilai buku perusahaan:
Ekuitas saben Saham IN8bio|INAB - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku in8bio.com|INAB - Aset Agregat Perusahaan
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal IN8bio, Inc.|INAB - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas IN8bio Inc|INAB - Utang kumulatif perusahaan|Utang marang nilai buku IN8bio, Inc|INAB - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan IN8bio|Likuiditas cepet in8bio.com
- indikator pendapatan resik lan kelipatan nilai:
INAB - Bathi perusahaan|Proyeksi bathi mangsa ngarep IN8bio, Inc.|INAB - Koefisien rega marang bathi|Prakiraan rega marang bathi IN8bio Inc.|INAB - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA IN8bio, Inc|INAB - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan IN8bio|INAB - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan in8bio.com|INAB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep IN8bio, Inc.
- data pendapatan lan penerimaan dodolan:
INAB - Pendapatan perusahaan|Prakiraan volume dodolan in8bio.com|INAB - Kapitalisasi marang pendapatan|Multiplikator Forward P/S IN8bio, Inc
Pambiji fundamental perusahaan:INAB (in8bio.com)
Produk mawa merek IN8bio Inc

The P/S chart allows for a comparison of the market capitalization of IN8bio, Inc. (INAB) against its current sales volume, reflecting the degree of asset overvaluation within the context of cell therapy development. This ratio is calculated by dividing the company's value by its revenue, helping investors assess the value of intellectual property and the monetization potential of patents for treating oncohematological diseases.

Pesaing utama

tgtherapeutics.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ACLX (Arcellx, Inc.)|Koefisien rega marang pendapatan Disc Medicine Inc (IRON)|SNDX - Rasio rega marang pendapatan|KURA (Kura) - Rasio kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ADC Therapeutics ADCT|Foghorn Therapeutics Inc. (FHTX) - Multiplikator P/S|Rasio rega marang pendapatan Vor Biopharma|Multiplikator P/S Nkarta Corp|COEP (Coeptis Therapeutics) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan ATNM (Actinium Corp)|ESLA: Rega marang dodolan|CASI - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan Marker Bio (MRKR)|ERNA - Multiplikator P/S|GT Biopharma Corp - Koefisien rega marang pendapatan|APTO (Aptose Biosciences) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan Bio-Path Holdings (BPTH)|Multiplikator P/S meipharma.com|Kapitalisasi marang pendapatan VINC (Vincerx Pharma, Inc.)